Ryoncil Commercial Launch Update and Product Pipeline Overview

Mesoblast Limited (ASX: MSB) is making significant strides with the U.S. commercial launch of Ryoncil for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is finalizing logistics, regulatory documentation, and distribution to ensure this quarter's successful launch.

With a recent US$160 million financing, Mesoblast has a proforma cash balance of approximately US$200 million to support commercialization, clinical expansion, and manufacturing scale-up. The company's late-stage pipeline includes Revascor for heart failure and Rexlemestrocel-L for chronic low back pain, both targeting multi-billion-dollar markets. Backed by extensive intellectual property, FDA compliance, and scalable manufacturing, Mesoblast is positioned as a leader in treating life-threatening inflammatory diseases with innovative, off-the-shelf cellular therapies.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com